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ABSTRACT
Objective: To determine the clinical outcomes for
patients with new-onset undifferentiated arthritis (UA),
not fulfilling the 2010 American College of
Rheumatology (ACR)/European League Against
Rheumatism (EULAR) rheumatoid arthritis (RA)
classification criteria, and the clinical and imaging
predictors of disease progression in these patients.
Methods: A prospective observational study was
conducted in treatment-naïve UA patients. Baseline
ultrasound involved semiquantitative assessment of
grey scale (GS) synovitis and power Doppler activity
(PD) at 26 joints. Outcomes were fulfilment of 2010
RA criteria ( joint involvement determined clinically)
and initiation of methotrexate over 12 months. Cox
proportional hazards analysis was used to investigate
predictors of outcome.
Results: Of 60 patients, 13(22%) progressed to RA
and 32(53%) ever received methotrexate. Analyses of
predictors of outcome were conducted in the subgroup
(n=41) of patients with complete baseline data. The
presence of GS was associated with progression to RA
and methotrexate use: HRs (95% CI) were 1.25(1.07 to
1.45) and 1.16(1.02 to 1.32), respectively, for the
number of joints with GS≥ grade 2 after adjustment for
swollen joints. PD was not predictive in the low levels at
which it was observed. Progression to RA was also
associated with fulfilment of the 2010 criteria using
ultrasound synovitis for enumerating joint involvement,
higher baseline disability and radiographic erosion.
Conclusions: This is the first report of ultrasound
findings in early UA (defined by presence of clinical
synovitis and non-fulfilment of 2010 RA criteria).
A significant proportion of patients with UA progressed
to RA and/or required methotrexate. GS synovitis was
predictive of disease progression.
INTRODUCTION
The 2010 American College of Rheumatology
(ACR)/European League Against
Rheumatism (EULAR) rheumatoid arthritis
(RA) classiﬁcation criteria provide a means
of identifying patients who are likely to
beneﬁt from methotrexate early in the
course of inﬂammatory arthritis.1–3 However,
Key messages
What is already known about this subject?
▸ Patients with new-onset undifferentiated arthritis
(UA) (defined historically by non-fulfilment of
the 1987 American College of Rheumatology
(ACR) rheumatoid arthritis (RA) criteria) are at
risk of progression to RA.
▸ Ultrasound-detectable synovitis is of prognostic
significance in these patients, although precise
definitions of imaging synovitis for use in strati-
fying risk of progression/disease severity in
practice are not yet available.
What does this study add?
▸ This study demonstrates approximately one in
five patients with UA, not fulfilling the new ACR/
European League Against Rheumatism (EULAR)
RA classification criteria, progress to fulfil the
criteria, despite contemporary assessment and
treatment practices.
▸ The severity of grey scale (GS) synovitis
detected across 26 joints was predictive of pro-
gression to RA (defined by 2010 criteria) and
methotrexate use, independently of the clinical
swollen joint count or disease activity score.
How might this impact on clinical practice?
▸ Ultrasound of up to 26 joints to determine the
presence of GS synovitis is potentially feasible
in patients presenting with new-onset UA and is
a valid tool for assessment of the need for
early disease-modifying anti-rheumatic drug
(DMARD) therapy.
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retrospective analyses of historic early arthritis cohorts
demonstrate patients with undifferentiated arthritis
(UA), not fulﬁlling these 2010 ACR/EULAR RA classiﬁ-
cation criteria, may also be at risk of progression to RA.4 5
The potential beneﬁts of disease-modifying anti-
rheumatic drug (DMARD) treatment may be lost if treat-
ment is delayed in these patients.6 Furthermore, there is
limited data concerning the natural history/progression
of disease in patients with UA in contemporary real-life
cohorts. Hence, there is a need to establish modern-day
disease outcomes for these patients and methods for pre-
dicting which of these patients are likely to have persist-
ent or progressive disease.
Imaging by ultrasound provides a sensitive method for
the detection of synovitis in comparison to clinical exam-
ination, while MRI is considered as the reference stand-
ard.7 8 Indeed, the 2010 RA criteria allow for joint
involvement to be determined by imaging evidence of
synovitis when at least one joint is clinically swollen.1
However, a deﬁnition for ultrasound synovitis is not spe-
ciﬁed. Studies supporting the prognostic value of ultra-
sound synovitis in patients with suspected early
inﬂammatory arthritis have previously been limited to
those deﬁning progression using the 1987 RA criteria.9 10
These criteria have poor sensitivity in early disease.11
Other studies have examined its value in predicting the
need for methotrexate (the standard for RA used in the
development of the 2010 criteria)12 as well as other mea-
sures of disease persistence.13–15 Participants of these
studies have included both patients lacking any clinical
joint swelling as well as those already fulﬁlling 2010 RA
criteria.12–15 Hence, the prognostic value of ultrasound
speciﬁcally in patients with UA, deﬁned by modern-day
criteria, is not fully understood.
First, the aim of this study was to determine the 1-year
outcomes of patients with new-onset UA (deﬁned by the
presence of clinical synovitis and non-fulﬁlment of 2010
RA classiﬁcation criteria). Second, associations between
baseline clinical and ultrasound imaging characteristics
and poor prognosis were evaluated. This is the ﬁrst study
to investigate the value of ultrasound in predicting the
development of RA, deﬁned by the 2010 RA criteria, in
patients with UA.
METHODS
Patients
A prospective observational cohort study was conducted
in the Leeds Early Arthritis Clinic. Since June 2010, all
DMARD-naïve patients with new-onset inﬂammatory
arthritis were invited to participate. Patients meeting the
following criteria were selected: (1) swelling of at least
one joint not explicable by a non-RA diagnosis and not
fulﬁlling 2010 ACR/EULAR RA criteria and (2) enrol-
ment up to August 2012. In determining patient eligibil-
ity, joint involvement within the 2010 criteria was
determined solely by clinical examination. Patients were
managed by consultant rheumatologists. Consent was
obtained from all participants. The study was approved
by the Leeds West Regional Ethics Committee.
Clinical assessments
Data collection at enrolment and every 3 months (or as
clinically indicated) thereafter included the disease activ-
ity score (DAS-CRP) using swollen joint count (SJC44),
the Ritchie Articular Index (RAI), patient visual ana-
logue scale assessment of global disease activity (VASDA)
and C reactive protein (CRP).
Imaging
At baseline, ultrasound examination was conducted for
26 joints (elbows, wrists, second-third metacarpophalan-
geal (MCP) and proximal interphalangeal (PIP) joints,
knees, ankles and ﬁrst-ﬁfth metatarsophalangeal (MTP)
joints). A GE E9 machine was used with 15-6 and
18–8 MHz linear array transducers. The scanning para-
meters were: B mode frequency (12–18 MHz), B mode
gain 44–54 db, power Doppler frequency (7.5–10 MHz),
pulse repetition frequency (PRF) 800 Hz (0.8 kHz) and
wall ﬁlter low–medium. Individual joints were scored for
grey scale (GS) synovitis and power Doppler activity
(PD) using a semiquantitative grading scale. GS synovitis
was graded according to the absence (grade 0) or pres-
ence of mild (grade 1), moderate (grade 2) or severe
(grade 3) hypoechoic synovial thickening. Power
Doppler synovitis was scored according to the following
categories: no ﬂow in the synovium/area of GS (grade
0), ≤3 single-vessel signals/≤2 areas of conﬂuent-vessel
signals/≤2 single-vessel signals and one area of conﬂu-
ent signal (grade 1), vessel signals in less than half of
the area of synovium (grade 2) and vessel signals in
more than half of the area of synovium (grade 3).
Scoring was performed according to a standard operat-
ing procedure showing probe positions and scoring
scenarios based on the EULAR/Outcome Measures in
Rheumatology Clinical Trials (OMERACT) system, illu-
strated in ﬁgure 1.16–18
Global measures of synovitis were total GS and PD
scores (sum of the individual scores at each of the 26
joints, ie, maximum 78) and the number of joints with
signiﬁcant GS or PD. In the absence of a standardised
deﬁnition for the latter,1 two levels of signiﬁcance were
considered: (1) GS≥ grade 2 for signiﬁcant GS and
PD≥ grade 1 for signiﬁcant PD, as used by other
groups,12 and (2) more stringent deﬁnitions, GS=
grade 3 at MTPs (GS≥ grade 2 at other joints) and
PD≥ grade 2 at wrists and MTP1 (PD≥ grade 1 at
other joints). The latter, more stringent deﬁnitions,
were considered due to recent ﬁndings in healthy con-
trols: GS= grade 2 having been frequently observed at
MTPs and PD= grade 1 observed at the wrists and ﬁrst
MTPs.19 Patients were also reclassiﬁed according to ful-
ﬁlment of the 2010 criteria with joint involvement
determined clinically and/or by signiﬁcant ultrasound
synovitis (signiﬁcant GS and/or PD as per the above
deﬁnitions).
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Radiologists provided a summary report of plain ﬁlm
radiographs of the hands and feet at baseline.
Outcomes
Primary outcomes over 12 months were: (1) progression
to fulﬁlment of 2010 RA criteria (enumerating joint
involvement solely by clinical examination) and (2) initi-
ation of methotrexate.
Statistics
Outcomes were reported in all patients. The last obser-
vation was carried forward for patients in whom
12-month data were missing.
Patients with incomplete clinical and imaging exami-
nations at baseline were excluded from further analyses.
Differences between included and excluded patients
were evaluated using χ2 or Fisher’s exact tests for cat-
egorical variables (as appropriate for numbers of
expected values), t-tests for continuous variables follow-
ing a normal distribution and Mann-Whitney U tests for
non-parametric data. Predictors of outcome were deter-
mined using Cox proportional hazards analysis. To
determine whether ultrasound measures were predictive
independently of clinical synovitis, adjustment was made
for SJC44 and DAS-CRP. The assumption that hazards
were proportional was checked.
RESULTS
Patients
Of 441 patients presenting with suspected new-onset
inﬂammatory arthritis, 60 patients with new-onset UA
were identiﬁed for inclusion (ﬁgure 2). Baseline
characteristics are shown in table 1.
Outcomes
Observations were carried forward for 10 patients in
whom 12-month data were not available. Reasons were
non-attendance (n=6), enrolment in a clinical trial (n=1,
receiving methotrexate ± adalimumab for UA), assess-
ment not clinically indicated in drug-free remission
(n=1) or unknown (n=2).
Of 60 patients with UA at baseline, 13 (22%) pro-
gressed to fulﬁl 2010 RA criteria over 12 months. The
proportion of patients progressing according to their
2010 RA classiﬁcation criteria score at baseline (score
of at least six out of 10 required for classiﬁcation as
deﬁnite RA)1 was: 0/2 with a score of one, 0/3 score
two, 2/12 (17%) score three, 3/24 (13%) score four
and 8/19 (42%) score ﬁve. Persistent UA was observed
in a further 32 (53%) patients (DMARD or corticoster-
oid exposure within the preceding 3 months in 31
patients and joint swelling without treatment in one
patient). Among the remaining 15 patients, outcomes
were resolution of synovitis (n=13) and alternative
Figure 1 Spectrum of ultrasound grey scale on the dorsal aspects of the wrists ((a) to (d)), MCPs ((e) to (h)), PIPs ((i) to (l)) and
MTPs ((m) to (p)): grade 0 ((a), (e), (i) and (m)), grade 1 ((b), (f ), ( j) and (n)), grade 2 ((c), (g), (k) and (o)) and grade 3 ((d), (h),
(l) and (p)). Courtesy of J. L. Nam et al, Leeds, reproduced with permission from Annals of the Rheumatic Diseases.18
C, capitate; L, lunate; MC, metacarpal; MCPs, metacarpophalangeal joints; MP, middle phalanx; MT, metatarsal; MTP,
metatarsophalangeal joints; PIPs, proximal interphalangeal joints; PP, proximal phalanx; R, radius.
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diagnoses (inﬂammatory osteoarthritis n=1, psoriatic
arthritis n=1).
Of the total 60 patients, 32 (53%) patients ever received
methotrexate. Eight of these patients had disease progres-
sing to RA (included in the total of 13 patients progres-
sing to RA, with alternative DMARDs/corticosteroids
being administered in ﬁve). Methotrexate was started
prior to progression in six and after progression in two.
Predictors of outcome
Forty-one patients had complete baseline data for ana-
lysis (ﬁgure 2). No statistically signiﬁcant differences
were observed between included and excluded patients
(table 1).
Progression to RA and the requirement for methotrex-
ate were signiﬁcantly associated with greater baseline GS
synovitis (table 2). These associations remained signiﬁ-
cant after adjustment for SJC44 and DAS-CRP.
Progression to RA was also associated with fulﬁlment of
2010 criteria including US synovitis in the determination
of joint involvement, presence of radiographic erosions
and Health Assessment Questionnaire (HAQ) score.
To further explore the signiﬁcant relationships
between baseline GS synovitis and clinical outcomes,
Kaplan-Meier survival plots were constructed (ﬁgure 3).
At least half of all patients with >4 joints with GS≥ grade
2 (or ≥2 joints meeting the higher threshold deﬁnition
for signiﬁcant GS, GS= grade 3 at MTPs 1-5 or ≥ grade 2
at other joints), continuing under follow-up at
12 months, had progressed to RA (ﬁgures 3A, B). In
comparison, among patients without any GS≥ grade 2 at
baseline no progression was observed. By 12 months,
methotrexate was required in up to one-third of patients
with at <2 joints with GS≥ grade 2 versus up to two-thirds
of patients with ≥2 joints with GS≥ grade 2 (ﬁgure 3C).
DISCUSSION
This is the ﬁrst study to demonstrate that ultrasound
synovitis predicts progression to fulﬁlment of the 2010
RA classiﬁcation criteria. On ultrasound examination ofFigure 2 Patient disposition.
Table 1 Baseline characteristics of patients included in the analysis of predictors of outcomes and those excluded due to
incomplete data. Values are median (IQR) or n (%), unless otherwise stated
All n=60
Subgroup for Analysis of predictors of
outcome
Included n=41 Excluded n=19 p Value
Age, mean (SD) 46 (14) 45 (15) 48 (11) 0.4
Female 39 (65%) 27 (66%) 12 (63%) 0.8
Symptom duration, months 9 (4–17) 9 (4–18) 8 (4–17) 0.8
ACPA positive 4 (7%) 3 (7%) 1 (5%) 1.0
Early Morning Stiffness ≥60 min 31 (52%) 19 (46%) 12 (63%) 0.3
RAI
SJC44
3 (2–6)a
2 (1–4)a
3 (2–6)
2 (1–5)
2 (1–3)a
2 (1–3)a
0.1
0.7
CRP, mg/L 7 (0–23) 6 (0–22) 10 (0–27) 0.4
Patient VASDA, mm 43 (25–66)a+b 45 (25–68)b 34 (17–63)a 0.7
DAS-CRP 2.3 (1.6–2.9)b+c 2.3 (1.8–2.9)b 1.8 (1.3–2.5)c 0.2
HAQ 0.3 (0.1–0.9)a+d 0.3 (0.1–0.9)d 0.6 (0.1–1.1)a 0.9
US of 26 joints at baseline: total GS score 9 (5–16)e 9 (5–17) NAe NA
Total PD score 1 (0–2)e 1 (0–2) NAe NA
Number of joints with GS≥ grade 2
Number of joints with PD≥ grade 1
2 (1–5)e
1 (0–1)e
2 (1–5)
1 (0–1)
NAe NA
Fulfilment of 2010 ACR/EULAR RA criteria with joint
involvement determined clinically or by GS≥ grade 2
and/or PD≥ grade 1
4/42 (10%) 4 (10%) NAe NA
Radiographic erosion in the hands and/or feet 4/55 (7%) 3 (7%) 1 (7%)f 1.0
Missing data in a12, b8, c13, d6, e18 and f5 cases.
ACPA, anti-cyclic citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C reactive protein; DAS-CRP, disease activity
score; EULAR, European League Against Rheumatism; GS, grey scale; HAQ, Health Assessment Questionnaire; NA, not applicable
(summary statistics not performed due to insufficient data); PD, power Doppler activity; RA, rheumatoid arthritis;RAI, Ritchie articular index;
SJC44, swollen joint count of 44 joints; US, ultrasound; VASDA, visual analogue scale disease activity assessment.
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Table 2 Subgroup analyses of patients with complete clinical examination and imaging data: association between baseline characteristics and progression to fulfilment of
2010 ACR/EULAR RA criteria and the requirement for methotrexate over 12 months (n=41). Values are median (IQR) or n (%) unless otherwise stated
Progression to RA Ever required methotrexate
Yes
n=9
No
n=32 HR (95 % CI) p Value
Yes
n=18
No
n=23 HR (95 % CI) p Value
Age, mean (SD) 48 (15) 44 (15) 1.01 (0.97 to 1.06) 0.5 46 (14) 43 (16) 1.01 (0.98 to 1.04) 0.7
Female 7 (78%) 20 (63%) 1.67 (0.35 to 8.04) 0.5 12 (67%) 15 (65%) 0.82 (0.31 to 2.18) 0.7
Symptom duration, months 12 (5-29) 9 (4-18) 1.00 (0.98 to 1.03) 0.8 15 (5-26) 6 (3-14) 1.01 (1.00 to 1.03) 0.04
ACPA positive 0 3 (9%) NA NA 1 (6%) 2 (9%) 0.72 (0.10 to 5.41) 0.7
Early Morning Stiffness ≥60 min 5 (56%) 14 (44%) 1.53 (0.41 to 5.69) 0.5 7 (39%) 12 (52%) 0.75 (0.29 to 1.95) 0.6
RAI 6 (3-8) 3 (2-6) 1.33 (0.99 to 1.79) 0.06 4 (3-6) 3 (1-6) 1.06 (0.88 to 1.28) 0.5
SJC44 4 (1-6) 2 (1-4) 1.12 (0.87 to 1.45) 0.4 3 (1-4) 2 (1-5) 0.98 (0.80 to 1.18) 0.8
CRP, mg/L 0 (0-10) 6 (0-22) 1.01 (1.00 to 1.03) 0.07 9 (0-28) 6 (0-17) 1.01 (0.99 to 1.02) 0.4
Patient VASDA, mm 59 (33-75)a 45 (23-64)b 1.03 (0.99 to 1.06) 0.1 64 (38-74)c 30 (17-60)d 1.03 (1.01 to 1.06) 0.02
DAS-CRP 2.8 (2.1-3.1)a 2.2 (1.9-2.6)b 3.15 (0.81 to 12.2) 0.1 2.2 (2.0-2.6)c 2.1 (1.5-2.7)d 1.75 (0.77 to 3.98) 0.2
HAQ 0.9 (0.1–1.3) 0.3 (0.1-0.8)e 3.73 (1.40 to 9.94) 0.009 0.5 (0.1-0.9)c 0.3 (0.1-0.8)c 1.04 (0.43 to 2.55) 0.9
Total GS score (unadjusted)
Adjusted for SJC44
Adjusted for DAS-CRP
16 (12-19) 8 (4-12) 1.11 (1.03 to 1.20)
1.11 (1.03 to 1.20)
1.10 (1.01 to 1.19)
0.008
0.008
0.03
12 (9-18) 7 (2-12) 1.09 (1.02 to 1.15)
1.09 (1.02 to 1.15)
1.09 (1.03 to 1.17)
0.01
0.01
0.02
Number of joints with significant GS synovitis:
-Any joint ≥ grade 2 (unadjusted)
Adjusted for SJC44
Adjusted for DAS-CRP
-MTPs= grade 3, other joints ≥ grade 2
(unadjusted)
Adjusted for SJC44
Adjusted for DAS-CRP
5 (4–8)
2 (1–3)
1 (0–3)
0 (0–1)
1.25 (1.07 to 1.45)
1.25 (1.07 to 1.45)
1.21 (1.03 to 1.43)
1.43 (1.10 to 1.87)
1.44 (1.09 to 1.91)
1.43 (1.05 to 1.95)
0.004
0.004
0.02
0.008
0.01
0.02
3 (1–6)
1 (0–3)
1 (0–3)
0 (0–2)
1.16 (1.02 to 1.32)
1.16 (1.02 to 1.32)
1.18 (1.01 to 1.38)
1.24 (0.99 to 1.54)
1.24 (0.99 to 1.53)
1.26 (0.96 to 1.94)
0.03
0.02
0.04
0.06
0.06
0.09
Total PD score (unadjusted)
Adjusted for SJC44
Adjusted for DAS-CRP
0 (0-1) 1 (0-2) 1.07 (0.70 to 1.63)
1.06 (0.69 to 1.63)
1.05 (0.71 to 1.56)
0.8
0.8
0.8
0 (0-2) 1 (0-2) 1.00 (0.76 to 1.31)
1.00 (0.76 to 1.32)
0.96 (0.71 to 1.28)
1.0
1.0
0.8
Number of joints with significant PD synovitis:
-Any joint ≥ grade 1 (unadjusted)
Adjusted for SJC44
Adjusted for DAS-CRP
-Wrists and MTP1 ≥ grade 2, other joints ≥
grade 1 (unadjusted)
0 (0–1)
0 (0–0)
1 (0–1)
0 (0–1)
0.94 (0.43 to 2.05)
0.91 (0.41 to 2.02)
0.97 (0.46 to 2.02)
1.12 (0.54 to 2.34)
0.9
0.8
0.9
0.8
0 (0–1)
0 (0–1)
1 (0–1)
0 (0–1)
0.85 (0.50 to 1.47)
0.85 (0.50 to 1.47)
0.85 (0.50 to 1.47)
1.13 (0.71 to 1.81)
0.6
0.6
0.7
0.6
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26 joints, the baseline total GS score and the number of
joints with signiﬁcant GS synovitis were associated with
progression and methotrexate use.
HRs for the risk of progression to 2010 RA with
increasing total GS score and number of joints with sig-
niﬁcant GS (GS≥ grade 2 or a more stringent deﬁnition
for signiﬁcant GS: GS=grade 3 at MTPs/grade 2 at other
joints) were of the order of 1.1, 1.2 and 1.4, respectively.
This suggests a 10%, 20% and 40% increase in the risk
of progression for each unit increase in total GS score or
each additional joint affected. CIs indicate some uncer-
tainty in these estimates (with the true increase in risk
likely lying between 3–20%, 7–45% and 10–87%, respect-
ively); however, the associations remained statistically sig-
niﬁcant after statistical adjustment for the number of
swollen joints/disease activity, without signiﬁcant change
in HRs or CIs. This demonstrates the added value of
ultrasound over clinical examination in the initial assess-
ment of patients who clinically do not fulﬁl the 2010 RA
criteria.
Results suggest the presence of at least two joints with
GS≥ grade 2 (of the 26 joints examined), was clinically
relevant to determining the future use of methotrexate.
For the purposes of predicting progression to RA, the
presence of at least ﬁve joints with GS≥ grade 2 (or at
least two joints with signiﬁcant GS deﬁned as grade 3 at
MTPs and ≥ grade 2 at other joints) appeared to dis-
criminate patients with low or high risk of progression. It
must be borne in mind that methotrexate initiation in
patients with UA in this observational study could feas-
ibly have prevented progression to RA in a proportion of
patients. Ultrasound examination of up to 26 joints, to
determine the presence of signiﬁcant GS synovitis
deﬁned by these thresholds, is potentially feasible within
time constraints in a clinical setting in patients present-
ing with UA.
If ultrasound-detected subclinical synovitis was used, in
addition to clinical examination, in deﬁning joint
involvement in the application of the 2010 RA criteria at
baseline, this was also predictive of clinical progression.
Although potentially speciﬁc in the prediction of pro-
gression, the sensitivity of this measure (on the basis of
the 26-joint ultrasound examination) was relatively low;
only four patients fulﬁlled the criteria including the less
stringent deﬁnition for signiﬁcant GS and/or PD syno-
vitis (GS≥ grade 2 and/or PD≥ grade 1) in the deﬁn-
ition of joint involvement, at baseline.
PD was infrequently observed in the 26-joint examin-
ation in this early UA cohort. When detected, it was not
associated with outcome; the statistical power to detect a
relationship being limited by the low levels of PD
observed. GS in untreated patients has previously been
shown to be predictive of persistent arthritis,13 15 the
need for methotrexate12 and progression to fulﬁlment
of the 1987 ACR RA criteria.9 In untreated patients it
probably has the same implications for prognosis as PD
which has also been associated with these outcomes and
the need for early DMARD therapy.9 10 12–14 In contrast,
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in late disease, after therapy, GS reﬂects previous inﬂam-
mation and correlates with disease duration,20 whereas
PD reﬂects inﬂammation at whatever stage of disease.
A high rate of DMARD use was observed in compari-
son to that reported in previous UA cohorts.4 This may
reﬂect increasing awareness of the beneﬁts of early
therapy. A signiﬁcant rate of progression to 2010 RA was
also observed, higher than that reported in a previous
study in the United Kingdom (10%), although patients
with >3 months of symptoms were excluded in this very
recent-onset UA cohort.5
Other studies investigating the predictive validity of
ultrasound in patients with at least one swollen joint
demonstrate rates of progression to fulﬁlment of 1987
RA over 12–18 months of 42–50%.9 10 Filer et al studied
58 patients with early inﬂammatory arthritis (26 of
whom already fulﬁlled the 2010 RA criteria at baseline).
Global GS and PD measures across 38 joints signiﬁcantly
increased the area under the curve when modelled with
the Leiden prediction score.21 Implications for clinical
practice are not immediately clear, particularly given
then number of joints to be examined in calculating a
global score and as use of the Leiden score is not rou-
tinely undertaken in clinical practice.9 Salafﬁ et al10
demonstrated the number of joints with PD≥ grade 2 in
the hands and wrists was predictive of progression, inde-
pendently of serological status, inﬂammatory markers
and presence of early morning stiffness >30 min. Of
note, no adjustment was made for clinical evidence of
synovitis. Ozgul et al22 studied patients with suspected RA
not fulﬁlling 1987 ACR RA criteria, but only examined
one US parameter which not precisely deﬁned (symmet-
ric polyarticular synovitis, with ‘synovitis’ deﬁned as any
sign of pathology including erosion, any synovial
hypertrophy or effusion or tendon abnormalities).
Importantly, all three of these studies included patients
fulﬁlling 2010 RA criteria at baseline. Arguably, these
patients are already considered to be at high risk for per-
sistent and/or aggressive disease, and may not all be con-
sidered for US assessment in daily clinical practice.
The observational study design suggests results are
generalisable to clinical practice. However, associations
with initiation of methotrexate may be affected by bias.
When baseline ultrasound was missing, patients were
excluded from subsequent analyses. However, comparing
baseline characteristics with included patients did not
identify any signiﬁcant differences from those with the
US data. Other limitations include the small sample size
(although similar to the aforementioned single-centre
early arthritis cohort studies).9 13 22 This precluded the
use of several variable multivariate analyses or stratiﬁca-
tion, for example, by baseline 2010 RA classiﬁcation cri-
teria score. Of particular note, only a small number of
patients were anti-cyclic citrullinated protein antibody
Figure 3 Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with
significant synovitis defined by GS≥ grade 2 at any of 26 joints, or (B) GS= grade 3 at MTPs 1–5 or ≥ grade 2 at any other joint,
(C) the need for methotrexate according to the number of joints with significant synovitis defined by GS≥ grade 2 at any of 26
joints. The number of patients per group at baseline is denoted by n. GS, grey scale; MTP, metatarsophalangeal; RA, rheumatoid
arthritis.
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(ACPA) positive; although patient numbers are too small
to draw any clinically meaningful conclusion it is interest-
ing that none of the ACPA positive patients progressed
to RA. Owing to the known prognostic signiﬁcance of
ACPA, it would also be useful to stratify for ACPA in
order to determine the value of US in ACPA positive and
ACPA negative patients in larger studies.
These results conﬁrm the prognostic value of ultra-
sound in the management of patients with early UA. In
particular, the degree of GS appears to be a sensitive
indicator of disease progression in DMARD-naïve
patients. The balance between the added value of
limited joint ultrasound and the clinical resources
required to perform it appears to be favourable.
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